antivir
agent
potenti
util
exacerb
asthma
jaideep
dhariw
michael
r
edward
sebastian
l
johnston
asthma
common
chronic
respiratori
diseas
preval
increas
respiratori
viral
infect
earli
life
suggest
increas
risk
develop
asthma
later
life
viru
infect
remain
singl
greatest
precipit
asthma
exacerb
develop
effect
antivir
treatment
remain
key
target
therapeut
intervent
discuss
role
respiratori
viral
infect
asthma
exacerb
highlight
current
potenti
antivir
agent
mechan
action
asthma
heterogen
airway
diseas
characteris
airway
inflamm
airway
hyperreact
revers
bronchoconstrict
airway
remodel
patient
experi
short
breath
fluctuat
normal
breath
pattern
also
period
episod
wheez
cough
asthma
treat
inhal
corticosteroid
without
therapi
includ
short
long
act
bronchodil
asthma
exacerb
ae
major
caus
morbid
mortal
healthcar
cost
associ
asthma
gener
defin
worsen
symptom
accompani
drop
lung
function
prompt
gp
consult
visit
emerg
room
extrem
case
ae
requir
oral
corticosteroid
therapi
supplement
oxygen
may
result
death
respiratori
viru
infect
account
least
exacerb
adult
children
among
respiratori
virus
human
rhinovirus
rv
far
common
virus
associ
import
respiratori
virus
trigger
ae
therefor
made
target
therapeut
intervent
review
discuss
potenti
two
therapeut
approach
one
target
host
factor
may
induc
natur
antivir
immun
addit
antivir
cytokin
manipul
host
immun
respons
administr
vaccin
secondli
target
viru
includ
small
molecul
inhibitor
viru
replic
viru
specif
immunotherapi
approach
summaris
figur
overwhelmingli
import
role
virus
play
ae
argu
time
care
reconsid
antivir
intervent
ae
respiratori
viru
infect
trigger
ae
virus
rv
respiratori
syncyti
viru
rsv
season
influenza
virus
metapneumovirus
coronavirus
bocavirus
may
trigger
ae
adult
children
atyp
bacteria
mycoplasma
pneumonia
pneumonia
chlamydophila
pneumonia
c
pneumonia
also
common
respiratori
pathogen
associ
ae
adult
children
major
virus
associ
ae
rv
account
approxim
ae
age
rv
member
picornavirida
posit
sens
ssrna
virus
genom
kb
divid
major
minor
group
base
receptor
utilis
major
group
rv
bind
minor
group
rv
bind
ldl
receptor
rv
may
also
classifi
base
nucleotid
sequenc
ident
rva
rvb
rvc
rvc
group
uniqu
sequenc
ldl
receptor
bind
site
suggest
use
uniqu
current
unknown
receptor
rv
repres
divers
group
virus
serotyp
known
estim
group
c
virus
rvc
may
caus
sever
ae
although
occur
current
unknown
northern
hemispher
rv
infect
precipit
increas
emerg
room
admiss
due
ae
known
asthma
epidem
occur
third
week
septemb
children
return
school
highlight
school
age
children
vector
rv
infect
crucial
role
ae
major
minor
group
rv
mous
model
rv
infect
rv
induc
exacerb
airway
allergen
challeng
also
recent
develop
anim
studi
mirror
human
data
gather
date
support
idea
rv
infect
augment
airway
inflamm
caus
allergen
sensitis
challeng
provid
evid
respiratori
virus
rv
exacerb
asthma
recent
studi
report
impair
innat
immun
viru
infect
import
pathogenesi
ae
reduc
capac
induc
type
interferon
ifn
ifna
ifnb
type
iii
ifn
ifnl
upon
challeng
respiratori
virus
dsrna
mimet
polyic
bronchial
epitheli
cell
bec
bronchoalveolar
lavag
bal
macrophag
dendrit
cell
dc
peripher
blood
mononuclear
cell
pbmc
person
asthma
recent
describ
importantli
defici
ifnl
also
strongli
relat
viru
load
ae
pathogenesi
sever
vivo
mechan
respons
impair
ifna
ifnb
ifnl
remain
poorli
understood
howev
studi
advoc
role
ifn
therapi
ae
recent
phase
ii
placebo
control
trial
inhal
ifnb
poorli
control
adult
atop
asthmat
perform
inhal
ifnb
start
report
clinic
cold
show
promis
reduc
rate
ae
group
increas
lung
function
viru
load
studi
patient
show
trend
lower
viru
load
treat
patient
therefor
inhal
ifnb
improv
ae
rate
associ
symptom
like
due
direct
antivir
activ
also
possibl
ifnb
could
modul
addit
process
respiratori
antivir
approach
may
prevent
virus
act
synergist
addit
manner
allergen
caus
immun
deviat
rather
immun
respons
antivir
approach
may
agent
prevent
viru
infect
replic
mucos
surfac
prevent
epitheli
damag
inflamm
mucou
product
activ
macrophag
attract
neutrophil
lung
promot
inflamm
damag
act
antagonist
immun
recent
studi
shown
ifnb
type
iii
ifnl
potent
antagonist
activ
suggest
inhal
ifnb
may
deliv
benefit
two
level
atop
asthma
firstli
reduc
viru
replic
henc
viru
driven
inflamm
secondli
dampen
respons
allergen
studi
inhal
ifnb
ae
eagerli
anticip
ketomacrolid
telithromycin
previous
shown
efficaci
ae
adult
asthmat
phase
iv
clinic
trial
mechan
respons
benefici
effect
unknown
telithromycin
could
mere
act
antiinflammatori
agent
cell
base
assay
azithromycin
close
relat
erythromycin
telithromycin
shown
antivir
activ
rv
induc
ifn
interferon
stimul
gene
isg
previous
unknown
properti
azithromycin
sinc
promot
investig
azithromycin
phase
iv
clinic
trial
ae
current
ongo
number
virus
implic
aetiolog
asthma
associ
antigen
divers
thu
far
limit
develop
effect
vaccin
number
potenti
rsv
vaccin
candid
although
none
current
licens
use
creation
effect
rsv
vaccin
significantli
affect
follow
use
formalin
inactiv
rsv
firsv
vaccin
led
increas
morbid
enhanc
respiratori
diseas
follow
infect
live
viru
subsequ
death
children
phenomenon
felt
result
induct
immun
respons
vaccin
new
develop
creation
vaccin
use
tlr
ligand
adjuv
agent
one
recent
studi
use
monophosphoryl
lipid
mpla
deriv
bacteri
lp
incorpor
rsv
virosom
demonstr
enhanc
respons
increas
product
ifng
decreas
anim
immunis
vaccin
challeng
viru
mpla
adjuv
vaccin
confer
similar
protect
live
rsv
viru
firsv
vaccin
evid
enhanc
respiratori
diseas
addit
use
mpla
led
enhanc
immunogen
rsv
vaccin
product
higher
affin
antibodi
vaccin
commerci
avail
recommend
use
influenza
annual
vaccin
shown
play
key
role
prevent
viru
infect
associ
morbid
prevent
approach
may
well
advantag
treatment
acut
viral
infect
current
treatment
option
limit
rv
infect
implic
vast
major
viru
induc
ae
perhap
attract
target
respiratori
vaccin
howev
serotyp
rv
unlik
influenza
limit
epidemiolog
inform
regard
import
circul
serotyp
human
infect
rv
earli
life
recurr
life
adult
antibodi
multipl
rv
strain
complic
human
studi
antibodi
respons
improv
diagnost
molecular
techniqu
recent
allow
identif
rvc
group
highlight
difficulti
select
specif
serotyp
vaccin
gener
major
hurdl
understand
antibodi
product
follow
viru
infect
scarciti
anim
model
allow
us
studi
asthma
exacerb
subsequ
effect
immunis
greater
detail
recent
paper
describ
novel
mous
model
rv
infect
immunis
allow
studi
rv
mediat
induct
antibodi
respons
paper
demonstr
gener
strong
crossserotyp
igg
respons
rv
capsid
protein
multipl
infect
necessari
induc
neutralis
antibodi
anoth
group
also
recent
shown
use
recombin
protein
abl
gener
neutralis
antibodi
display
crossreact
distantli
relat
rv
strain
studi
suggest
effort
develop
rv
vaccin
may
worth
revisit
use
small
molecul
inhibitor
rv
infect
replic
releas
popular
theme
treatment
common
cold
despit
approach
show
promis
common
cold
studi
use
antivir
yet
examin
viru
induc
ae
small
molecul
antivir
offer
advantag
cost
effect
small
molecul
product
valid
select
safeti
rel
straightforward
establish
disadvantag
may
limit
specif
viru
type
may
select
escap
mutant
time
may
suffer
toxic
side
effect
continu
use
antirv
agent
pleconaril
use
randomis
placebocontrol
phase
ii
clinic
trial
treatment
common
cold
pleconaril
prevent
uncoat
serotyp
rv
pleconaril
test
therapeut
agent
infect
individu
begin
therapi
day
experienc
clinic
cold
pleconaril
show
signific
improv
mean
symptom
score
decreas
mean
durat
ill
despit
promis
initi
result
pleconaril
abandon
treatment
due
side
effect
rv
proteas
inhibitor
ruprintrivir
test
doubl
blind
placebocontrol
phase
ii
trial
experiment
challeng
ruprintrivir
design
bind
irrevers
rv
activ
site
prophylaxi
ruprintrivir
reduc
mean
total
symptom
score
viral
titr
nasal
secret
incid
frequenc
clinic
cold
therapeut
treatment
ruprintrivir
also
reduc
symptom
score
nasal
secret
viral
titr
solubl
icam
deriv
tremacamra
test
randomis
doubleblind
placebocontrol
studi
therapeut
prophylact
intervent
challeng
tremacamra
show
promis
therapi
reduc
frequenc
cold
total
symptom
score
nasal
mucu
weight
viru
induc
inflamm
quercetin
polyphenol
rang
properti
antivir
quercetin
thought
inhibit
inhibit
inhibit
viral
endocytosi
rv
polioviru
proteas
activ
rna
polymeras
activ
rna
virus
mous
model
rv
infect
quercetin
given
infect
reduc
viru
titr
improv
lung
function
howev
given
daili
day
finish
hour
rv
infect
quercetin
littl
effect
viru
replic
lung
function
develop
drug
abandon
variou
reason
howev
consid
role
virus
ae
avail
human
mous
model
viru
induc
ae
never
better
time
trial
small
molecul
antivir
therapi
ae
futur
like
wit
studi
antivir
potenti
treatment
virusinduc
ae
recombin
monoclon
antibodi
mab
palivizumab
licenc
use
human
rsv
immunoprophylaxi
sinc
act
epitop
region
rsv
fusion
protein
shown
reduc
rate
hospitalis
high
riskinf
use
prophylact
scarciti
evid
regard
role
palivizumab
treatment
acut
rsv
diseas
evid
predominantli
limit
case
report
small
retrospect
studi
singl
dose
mgkg
children
intub
respiratori
failur
due
rsv
shown
reduc
rsv
concentr
tracheal
aspir
palivizumab
shown
well
toler
adult
stem
cell
transplant
recipi
howev
need
larg
scale
studi
assess
role
palivizumab
therapi
rsv
infect
motavizumab
medimmun
second
gener
mab
develop
palivizumab
affin
matur
comparison
palivizumab
shown
bind
rsv
f
protein
better
approxim
improv
neutralis
rsv
vitro
well
abl
reduc
pulmonari
rsv
titr
lower
equival
dose
palivizumab
motavizumab
abl
inhibit
viral
replic
upper
respiratori
tract
make
potenti
attract
therapi
treatment
rsv
infect
studi
compar
motavizumab
palivizumab
rsv
prophylaxi
show
motavizumab
treatment
result
fewer
rsv
relat
lower
respiratori
tract
infect
need
medic
attent
howev
studi
also
document
increas
cutan
hypersensit
reaction
motavizumab
current
licenc
use
human
grow
bodi
work
direct
toward
gener
mab
influenza
two
recent
describ
mab
shown
broadli
neutralis
group
influenza
subtyp
antibodi
gener
singl
cell
cultur
plasma
cell
individu
follow
natur
influenza
infect
vaccin
passiv
transfer
mab
protect
mice
ferret
subtyp
identifi
singl
healthi
donor
neg
histori
influenza
preced
decad
demonstr
neutralis
activ
group
subtyp
act
region
near
ha
stem
identifi
new
mechan
underli
virushost
interact
new
area
interest
develop
antivir
therapi
current
mab
avail
use
rv
current
treatment
option
ae
limit
develop
littl
recent
year
furthermor
treatment
address
caus
exacerb
specif
mechan
involv
pathogenesi
new
clinic
studi
need
understand
mechan
viru
induc
ae
target
develop
novel
approach
prevent
therapi
identifi
antivir
therapi
may
sourc
new
therapi
review
highlight
potenti
therapi
target
viru
boost
host
respons
viru
latter
approach
base
recent
studi
show
impair
abil
asthmat
host
rais
effect
antivir
immun
respons
sever
potenti
way
restor
altern
viru
may
target
use
specif
antivir
immunotherapi
believ
futur
like
see
greatli
increas
studi
antivir
therapi
one
form
anoth
treatmentprevent
viru
induc
ae
